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The present study aimed to compare cancer incidence and trends in survival for chil-
dren diagnosed in Japan and England, using population-based cancer registry data.
The analysis was based on 5192 children with cancer (age 0-14 years) from 6 prefec-
tural cancer registries in Japan and 21 295 children diagnosed in England during
1993-2010. Differences in incidence rates between the 2 countries were measured
with Poisson regression models. Overall survival was estimated using the Kaplan–
Meier method. Incidence rates for Hodgkin lymphoma, renal tumors and Ewing sar-
comas in England were more than twice as high as those in Japan. Incidence of germ
cell tumors, hepatic tumors, neuroblastoma and acute myeloid leukemia (AML) was
higher in Japan than in England. Incidence of all cancers combined decreased in
Japan throughout the period 1993 to 2010, which was mainly explained by a
decrease in registration of neuroblastoma in infants. For many cancers, 5-year sur-
vival improved in both countries. The improvement in survival in chronic myeloid leu-
kemia (CML) was particularly dramatic in both countries. However, 5-year survival
remained less than 80% in 2005-2008 in both countries for AML, brain tumors, soft
tissue sarcomas, malignant bone tumors and neuroblastoma (age 1-14 years). There
were significant differences in incidence of several cancers between countries, sug-
gesting variation in genetic susceptibility and possibly environmental factors. The
decrease in incidence for all cancers combined in Japan was related to the cessation
of the national screening program for neuroblastoma. The large improvement in sur-
vival in CML coincided with the introduction of effective therapy (imatinib).
K E YWORD S
cancer registry data, childhood cancer, childhood cancer incidence and survival, epidemiology,
population-based study
1 | INTRODUCTION
Every year approximately 215 000 children (aged 0-14 years) are
diagnosed with cancer globally, while 80 000 children die from the
disease.1 Epidemiological analyses of differences in incidence and
survival between countries and over time are important to under-
stand etiological factors and to monitor changes in disease burden
and progress in the treatment of childhood cancers.
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The incidence of childhood cancer overall and by diagnostic sub-
group has been reported in the International Incidence of Childhood
Cancer (IICC) for many countries, including Japan and England.2,3 In
Europe, survival analysis has been performed to evaluate the quality
of care for children with cancer in each country or region in several
studies, including the Automated Childhood Cancer Information Sys-
tem (ACCIS)4 and EUROCARE-5.5 In 2012, the global surveillance of
cancer survival program (the CONCORD-2 study),6,7 which includes
childhood leukemia, was initiated using population-based cancer reg-
istry data from 67 countries. In Japan, population-based studies for
childhood cancer comparisons to other countries are scarce,
although some recent studies show childhood cancer incidence8,9 or
survival,10 and several cancer registries contributed to the IICC and
CONCORD-2 studies.2,7 In England, population-based incidence and
survival for childhood cancer have been reported since 1980s.11-13
In the current study, we compared incidence and time trends in sur-
vival for childhood cancer between Japan and England during the
period 1993-2010, to gain insight into the progress against child-
hood cancer in both countries.
2 | METHODS
2.1 | Data
This study was based on data from population-based cancer reg-
istries in Japan and England. It included all children (0-14 years)
diagnosed with cancer between 1993 and 2010 residing in 6 Japa-
nese prefectures (Miyagi, Yamagata, Niigata, Fukui, Osaka and Naga-
saki)10 or in England. Japanese data were obtained from the
Monitoring of Cancer Incidence in Japan (MCIJ) project and the
Japanese Cancer Survival Information for Society (J-CANSIS) pro-
ject,10 while data for England were obtained from the Office for
National Statistics. A standard set of variables included basic demo-
graphic data (age, sex and country), information on the tumor (date
of diagnosis, site and morphology) and on follow-up (date of last
contact and vital status). Follow-up information was available at
least 5 years after diagnosis in Japan although the patient follow-up
system differs for each cancer registry.10 Within the Japanese data,
vital status information was available for patients diagnosed during
1993-2008. In the English data, the vital status was last updated on
31 December 2015.
We included only records of malignant cancers (behavior code/3)
defined in the International Classification of Disease for Oncology,
3rd edition (ICD-O-3).14 Non-malignant or borderline central nervous
system tumors such as craniopharyngioma, meningioma, gangli-
oglioma, benign teratoma and pilocytic astrocytoma were all
excluded. Skin carcinomas were also excluded. Cancers were
grouped into 12 main diagnostic categories according to the Interna-
tional Classification of Childhood Cancer, 3rd edition (ICCC-3).15 We
modified some subgroups of ICCC-3, based on the topography and
morphology codes from ICD-O-3 (Table S1).
These data partially overlapped with the data used in the IICC or
CONCORD-2, although for participating registries or study periods,
inclusion criteria were not completely matched. There were few dis-
crepancies in the incidence of each cancer between both datasets,
with the exception of central nervous system (CNS) tumors and all
cancers combined.
2.2 | Statistical analysis
Incidence rates were calculated as the average annual number of
children newly diagnosed with cancer per million children. Age-
standardized incidence rates (ASR) were calculated by the direct
method, using the weights of the world standard population for
the age groups under 15 years (0, 1-4, 5-9 and 10-14 years).16,17
Changes in incidence rates over time were calculated using a Pois-
son regression model, divided into 3 time periods (1993-1998,
1999-2004 and 2005-2010) and adjusted for age-group, and
expressed as average annual percent change (AAPC). Differences in
incidence rates between the 2 countries were measured with Pois-
son regression models and expressed as the incidence rate ratio
(IRR), using English data as the reference. These ratios were
adjusted for time period and age group. Observed population-based
survival was estimated by cancer type in each time period (1993-
1996, 1997-2000, 2001-2004 and 2005-2008), using the Kaplan–
Meier method. We used the classic cohort approach to calculate 1-
year and 5-year survival for children diagnosed during 1993-2008,
and 10-year survival for children diagnosed during 1993-2000 in
Japan and during 1993-2004 in England. We used the period
approach to predict 10-year survival for children diagnosed during
2001-2008 in Japan and during 2005-2008 in England, as this
approach allows for the prediction of survival where 10-year fol-
low-up is not yet available.18 The analysis was carried out using
Stata 14. This study was approved by the London-South East
Research Ethics Committee (07/MRE01/52) and the Research
Ethics Committee of the Osaka International Cancer Institute (No.
1707105096).
3 | RESULTS
3.1 | Data quality
Analyses were based on 5192 cases in Japan and 21 295 cases in
England between 1993 and 2010. Table 1 shows the quality criteria
for validity and completeness of the data over time in each country.
The proportion of records from death certificate only (DCO) in
Japan reduced from 3.1% in 1993-1998 to 0.9% in 2005-2010,
whereas that in England has been stable at under 1% since 1993.
The proportion of unspecified histology (not otherwise specified
[NOS], ICD-O-3 morphology code 8000 to 8004) also decreased
from 4.3 to 2.1% in Japan, whereas that in England was around 2%
from 1993 to 2010.19 The proportion of multiple primary cancers
was under 1% in both countries, except in the Japanese data for
2005-2010. We included NOS for both incidence and survival analy-
sis while DCO and multiple primary cancers were excluded in sur-
vival analysis.
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3.2 | Trends in incidence of childhood cancer in
Japan and England
Table 2 shows trends in incidence for each cancer type in both
countries. Overall, the age-standardized incidence rate (ASR) of all
childhood cancers combined seemed to decrease in Japan (ASR
1993-1998: 127 per million vs 2005-2010: 116 per million; see
Table 2 and Figure S1A). However, incidence for all cancers except
neuroblastoma was stable (AAPC = 0.2%, [95% CI 0.4-0.8],
Table 2). A steep decline was observed in neuroblastoma (NBL) in
infants (age <1 year) in Japan (average age-specific incidence rate
changed from 191 to 27 per million; Table 2, Figure S1B). In Eng-
land, the incidence of all childhood cancers increased from 1993-
1998 to 1999-2004, and plateaued (ASR 1993-1998:129, 1999-
2004: 133, 2005-2010:134). Incidence increased significantly during
1993-2010 in England for malignant bone tumors (AAPC = 1.3%,
[95% CI 0.1-2.5]) and germ cell tumors (GCT; AAPC = 1.6%, [0.1-
3.1]), but not for the other cancer types.
3.3 | Comparison of incidence of each cancer type
between countries
Table 3 and Figure 1 show ASR in the total period of 1993-2010 and
the incidence rate ratios (IRR) for each cancer type between Japan and
England (England reference), adjusted for time period and age group.
Incidence rates for leukemias (IRR = 0.9, [95% CI 0.9-1.0], P < .01),
acute lymphoblastic leukemias (ALL) (IRR = 0.8, [0.7-0.8], P < .01),
lymphomas (IRR = 0.7, [0.7-0.8], P < .01), Hodgkin lymphomas (HL;
IRR = 0.1, [0.1-0.2], P < .01), malignant CNS tumors (IRR = 0.8, [0.7-
0.8], P < .01), astrocytoma (IRR = 0.6, [0.6-0.7], P < .01), medulloblas-
toma (IRR = 0.7, [0.6-0.8], P < .01), renal tumors (IRR = 0.4, [0.3-0.5],
P < .01), malignant bone tumors (IRR = 0.8, [0.7-0.9], P < .01), Ewing
sarcoma family of tumors (Ewing sarcomas, in both bone and soft tis-
sue; IRR = 0.5, [0.4-0.7], P < .01), soft tissue sarcomas (IRR = 0.8,
[0.7-0.9], P < .01), rhabdomyosarcomas (IRR = 0.7, [0.6-0.8], P < .01)
and other carcinomas (IRR = 0.7, [0.6-0.9], P < .01) were significantly
higher in England than Japan. Moreover, incidence rates for HL, renal
tumors and Ewing sarcomas in England were over twice as high as
those in Japan. Incidence rates for acute myeloid leukemias (AML;
IRR = 1.5, [1.3-1.6], P < .01), chronic myeloid leukemias (CML,
IRR = 1.4, [1.0-1.9], P = .044), NBL (IRR = 1.7, [1.5-1.8], P < .01), hep-
atic tumors (IRR = 1.7, [1.4-2.1], P < .01) and GCT (IRR = 1.8, [1.6-
2.1], P < .01) were significantly higher in Japan than England. Inci-
dence rates for non-Hodgkin lymphomas (NHL), NBL (children aged 1-
14 years), retinoblastoma, osteosarcomas and soft tissue sarcomas
(excluding RMS and Ewing sarcomas) were similar in Japan and Eng-
land, and the differences were non-significant. Incidence rates of
unspecified subtypes in each cancer group were higher in Japan than
in England for leukemias (IRR = 2.1, [1.6-2.7], P < .01), lymphomas
(IRR = 1.7, [1.3-2.2], P < .01), CNS tumors (IRR = 2.8, [2.2-3.5],
P < .01) and GCT (IRR = 2.2 [1.1-4.5], P = .02).
We analyzed age-specific incidence rates by sex for some solid
tumors (Wilms tumor, hepatoblastoma and GCT of each site) in each
country (Table S2 and Figure S2). The peak age for Wilms tumor in
Japan was infants aged under 1 year, whereas in England it was chil-
dren aged 1-4 years. Hepatoblastoma was the most common type of
hepatic tumor in both countries (N = 100 [88%] in Japan vs
N = 211 [82%] in England) and the age distribution was similar
between countries. Age-specific incidence rates for intracranial GCT
were higher in Japan than in England for all age groups. Incidence of
gonadal GCT in male infants in Japan was much higher than in Eng-
land. However, the numbers were too small to perform any relevant
statistical comparison.
3.4 | Trends in survival for each cancer type in
Japan and England
We analyzed trends in 1-year, 5-year and 10-year survival for each
cancer type and each period in both countries (Table 4). One-year
survival was over 80% in most cancers in both countries in the per-
iod 2005-2008, except for hepatic tumors (76%) in Japan and AML
(79%) and CNS tumors (75%) in England. Five-year survival for
TABLE 1 Indicators of data quality of population-based cancer registries between Japan and England
Records
Unspecified histologya DCOb
Multiple primary
cancersb
N N % N % N %
Japan (6 cancer registries)
1993-1998 1947 84 4.3 60 3.1 15 0.8
1999-2004 1704 74 4.3 21 1.2 15 0.9
2005-2010 1541 32 2.1 14 0.9 33 2.1
England
1993-1998 7019 152 2.2 38 0.5 35 0.5
1999-2004 7087 101 1.4 14 0.2 49 0.7
2005-2010 7189 169 2.4 14 0.2 50 0.7
DCO, records registered from death certificate only.
aICD-O-3 morphology code 8000 to 8004.
bWe included for incidence analysis, but excluded for survival analysis.
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leukemias significantly improved from 1993-1996 to 2005-2008,
reaching over 80% in 2005-2008 in both countries (Japan: 71%
[95% CI 67-75] to 83% [79-86], England: 76% [74-78] to 88% [86-
90]), whereas 5-year survival for CNS tumors remained at 50% in
both countries. Ten-year survival was over 80% for ALL (children
aged 1-14 years), CML, lymphomas, NBL infants (age <1 year),
retinoblastoma, renal tumors and germ cell tumors in both countries.
To calculate 10-year survival in recent periods, we used a different
approach (period approach) from the cohort approach, so there was
divergence between 5-year survival and 10-year survival (higher sur-
vival in 10-year survival than 5-year survival) in some cancers (lym-
phomas, NBL, renal tumors, and unspecified cancers in Japan, and
AML, CML, NBL infants, and GCT in England). Figure 2 illustrates 5-
year survival for most types of childhood cancers in Japan and Eng-
land in 1993-1996 and in 2005-2008. Difference in 5-year survival
between countries narrowed from 1993-1996 to 2005-2008 for
CML, lymphomas, CNS tumors, retinoblastoma, soft tissue sarcomas
and RMS. In contrast, 5-year survival was still less than 80% in both
countries even in the most recent period for AML (Japan: 78%, Eng-
land: 66%), CNS tumors (Japan: 59%, England: 57%), NBL children
aged 1-14 years (Japan: 75%, England: 57%), malignant bone tumors
(Japan: 67%, England: 65%), soft tissue sarcomas (Japan: 68%, Eng-
land: 73%) and RMS (Japan: 59%, England: 70%). Figure 3 shows the
changes in 5-year survival for each cancer type (except for other car-
cinomas and unspecified cancers) in each country from 1993-1996
to 2005-2008. Five-year survival improved for most cancers except
for renal tumors in Japan, and CNS tumors and NBL infants in Eng-
land. Survival for CML dramatically improved in both countries
(Japan: 67% to 100%, England: 44% to 84%).
4 | DISCUSSION
In this study, we compared incidence and trends in survival for each
childhood cancer type in Japan and England. Incidence of all child-
hood cancers combined decreased in Japan throughout 1993-2010
(Table 2, Figure S1A), whereas in England incidence for all cancers
combined was stable from 1999-2004 to 2005-2010, after a slight
increase in the earlier period. However, analysis of the incidence by
cancer type showed that the trends in cancer-specific incidence
hardly varied in each county, except for neuroblastoma in Japan
(Table 2). The apparent drop in incidence for neuroblastoma in Japan
was probably due to the cessation of the national screening program
for neuroblastoma, which had been conducted as urine tests for all
infants at 6 months of age since 1985.20,21 The Ministry of Health,
Labour and Welfare terminated the program in 2004 on the basis of
the self-healing potential of infant NBL and the negative effects of
screening on mortality.22 In the most recent period, after the cessa-
tion of this screening program in Japan, incidence for all cancers was
higher in England than in Japan (ASR 2005-2010 139 vs 116). The
incidence of many cancer types differed between Japan and England.
In England, incidence of HL, renal tumors and Ewing sarcomas was
more than double that of Japan. Previous studies have shown racialT
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differences in incidence for these cancers.23-29 Etiological factors of
HL have been suggested by the bimodal age distribution, by elevated
risks in males, by the occurrence of Epstein–Barr virus in HL tumor
cells, and by identifying inherited susceptibility genes; however, the
mechanism by which racial differences in incidence for HL occur is
still unclear. Regarding renal tumors, previous studies which reported
on differences in age distribution between countries for Wilms
tumor showed the peak age for occurrence in East Asia to be infants
(age <1 year), but among Caucasians in the USA the peak occurrence
was older.24,25 Our study supports these findings (Table S2 and Fig-
ure S2). Some other reports show differences in epigenetic factors in
Wilms tumor between Japanese and Caucasians.26,27 For Ewing sar-
comas, one report showed that Japanese Ewing sarcoma patients
have a higher frequency of loss of chromosome 19 than European
Caucasian patients.28 However, these tumors are rare and their etiol-
ogy has not been sufficiently investigated to explain these differ-
ences in incidence.29 Regarding the higher incidence of AML in
Japan, Bessho reported the mis-classification of ALL to ANLL (AML),
TABLE 3 Age-standardized incidence rate (ASR) and incidence rate ratio (IRR, England reference) of childhood cancer (age 0-14 y) in Japan
and England, 1993-2010
Japan England
IRR [95%CI] P-valueN ASR [95%CI] N ASR [95%CI]
I. Leukemias 1794 42.0 [40-44] 7391 46.8 [45.7-47.8] 0.9 [0.9-1] <.01
ALL 1156 27.3 [25.7-28.8] 5766 36.7 [35.7-37.6] 0.8 [0.7-0.8] <.01
AML 474 10.9 [9.9-11.9] 1203 7.4 [7-7.9] 1.5 [1.3-1.6] <.01
CML 53 1.1 [0.8-1.5] 139 0.8 [0.7-0.9] 1.4 [1-1.9] .044
Unspecified leukemias 81 2.0 [1.5-2.4] 147 0.9 [0.8-1.1] 2.1 [1.6-2.7] <.01
II. Lymphomas 509 11.1 [10.2-12.1] 2481 14.1 [13.5-14.6] 0.8 [0.7-0.8] <.01
Hodgkin lymphomas 38 0.8 [0.5-1] 1039 5.6 [5.3-6] 0.1 [0.1-0.2] <.01
Non-Hodgkin lymphomasa 321 6.9 [6.1-7.7] 1157 6.7 [6.3-7.1] 1.0 [0.9-1.2] .7
Unspecified lymphomas 92 2.0 [1.6-2.4] 188 1.1 [0.9-1.3] 1.7 [1.3-2.2] <.01
III. CNS tumors 796 18.0 [16.7-19.3] 3719 22.8 [22-23.5] 0.8 [0.7-0.9] <.01
Astrocytoma 210 4.5 [3.9-5.1] 1222 7.4 [7-7.8] 0.6 [0.6-0.7] <.01
Medulloblastoma 184 4.2 [3.6-4.9] 1031 6.3 [5.9-6.7] 0.7 [0.6-0.8] <.01
Unspecified CNS tumors 129 2.9 [2.4-3.4] 173 1.1 [0.9-1.2] 2.8 [2.2-3.5] <.01
IV. Neuroblastoma 604 16.2 [14.9-17.5] 1405 9.6 [9.1-10.1] 1.7 [1.5-1.8] <.01
NBL children aged 1-14 y 268 7.5 [6.6-8.4] 971 7.1 [6.6-7.5] 1.1 [0.9-1.2] .46
V. Retinoblastoma 170 4.6 [3.9-5.3] 647 4.5 [4.2-4.9] 1.0 [0.9-1.2] .78
VI. Renal tumors 135 3.5 [2.9-4.1] 1332 8.9 [8.5-9.4] 0.4 [0.3-0.5] <.01
VII. Hepatic tumors 113 2.9 [2.4-3.5] 256 1.7 [1.5-1.9] 1.7 [1.4-2.1] <.01
VIII. Malignant bone tumors 233 4.5 [3.9-5.1] 1044 5.7 [5.3-6] 0.8 [0.7-0.9] <.01
Osteosarcomas 148 2.8 [2.4-3.3] 558 3.0 [2.7-3.2] 1.0 [0.8-1.1] .57
Ewing sarcomas (bone and soft tissue)b 76 1.5 [1.2-1.9] 518 2.9 [2.6-3.1] 0.5 [0.4-0.7] <.01
Unspecified malignant bone tumors 9 0.2 [0.1-0.3] 49 0.3 [0.2-0.4] 0.7 [0.3-1.4] .26
IX. Soft tissue sarcomas 295 6.6 [5.9-7.4] 1449 8.8 [8.4-9.3] 0.8 [0.7-0.9] <.01
Rhabdomyosarcomas (RMS) 148 3.4 [2.8-3.9] 788 5.0 [4.6-5.3] 0.7 [0.6-0.8] <.01
Soft tissue sarcomas (excluding RMS
and Ewing sarcomas)
124 2.8 [2.3-3.3] 536 3.1 [2.9-3.4] 0.9 [0.7-1] .122
Unspecified soft tissue sarcomas 22 0.5 [0.3-0.7] 127 0.7 [0.6-0.9] 0.6 [0.4-1.0] .05
X. Germ cell tumors 359 7.8 [7-8.6] 724 4.3 [4-4.7] 1.8 [1.6-2.1] <.01
Unspecified malignant gonadal tumors 13 0.3 [0.1-0.4] 21 0.1 [0.1-0.2] 2.2 [1.1-4.5] .02
XI. Other carcinomas 132 2.6 [2.1-3] 646 3.6 [3.3-3.8] 0.7 [0.6-0.9] <.01
XI. Unspecified cancers 52 1.2 [0.9-1.5] 201 1.2 [1.1-1.4] n.a.
Total 5192 121.1 [117.8-124.5] 21295 132.0 [130.2-133.7] 0.9 [0.9-0.9] <.01
ALL, acute lymphoblastic leukemias; AML, acute myeloid leukemias, CML, chronic myeloid leukemia; CNS, central nervous system; NBL, neuroblastoma.
IRR were adjusted for time period and age group (using England as the reference). n.a., IRR of “unspecified cancers” (ICCC-3 group XII) were not calcu-
lated because models were not fitted.
aThis includes Burkitt lymphoma.
bEwing sarcoma family of tumors, in both bone and soft tissue.
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which overestimated the proportion of ANLL in the 1970s.30 How-
ever, nowadays, diagnosis of leukemia has become much more accu-
rate and the proportion of unknown leukemia subtype was only
approximately 5% in our data (Table 3). The ALL:AML ratio in our data
was 2.4:1, which is similar to that found in the report of the Japanese
pediatric leukemia study group (JPLSG), containing information on
molecular abnormalities collected by pediatric oncologists (ALL:
AML = 2.8:1).31 On the IICC-3 website, the ASR of AML was around
10 per million person-years in Japan and Korea,32 whereas the figure
was around 7 per million person-years in an Austria-based study.19
The CONCORD-2 study on cancer survival reported higher propor-
tions of AML in Asia than in Europe.7 In the US data, there are no large
racial differences in incidence for AML.33 Further research will be
needed to clarify whether the differences we have observed are due
to underlying ethnic difference in the incidence of AML.
When comparing incidence for each subgroup, the proportion of
“unspecified” histology within each cancer group should be taken
into account (Table 3). The proportion of “unspecified” lymphomas
(ICCC-3 II-e; 18%) or “unspecified” CNS tumors (ICCC-3 III-f; 16%)
in Japan was over 10% within each cancer group in the total period
(1993-2010), although it decreased to under 10% in the most recent
periods (data not shown).
Five-year survival for most cancer types improved in both Japan
and England. (Table 4). For example, survival of childhood leukemias
improved constantly in both countries throughout 1993-2008. Risk
stratification and improvement in clinical trials/treatment may have
contributed to the improvement in survival for ALL (children aged 1-
14 years) and AML in both countries.31,34-36 Survival in CML improved
dramatically in both countries after the introduction of the tyrosine
kinase inhibitor (TKI) imatinib (trade name Gleevec) approved by the
US FDA, Japan and the UK in 2001 (Figure 3).37 This is an impressive
example of an effective therapy changing the survival of patients dra-
matically. For survivors, however, careful, long-term follow-up is
needed because several case reports have described growth impair-
ment of pediatric CML patients as an adverse effect of imatinib.38,39
Differences in 5-year survival in some cancer types (CML, lymphomas,
CNS tumors, retinoblastoma, soft tissue sarcomas and rhabdomyosar-
coma) between countries seem to be narrowing (Figure 2). This may
be the result of recent international collaboration between countries.
However, even for the most recent periods, 5-year survival for several
cancer types (AML, CNS tumors, NBL [children aged 1-14 years], soft
tissue sarcomas, malignant bone tumors) remains <80% in both coun-
tries. To improve survival for patients with these cancer types, we
should target research at developing new drugs and improving treat-
ment protocols. Five-year survival of renal tumors in Japan, NBL under
1 year of age and CNS tumors in England decreased in the more
recent period (Figure 3). One possible reason for the latter is that
more cases of pilocytic astrocytoma could have been coded and classi-
fied as astrocytoma NOS or glioma NOS (both with the malignant
behavior code) in the earlier years.
4.1 | Cancer strategy for childhood cancer
Since 1974, the Japanese Government has subsidized medical
expenses for children and adolescents under 18 years of age with
cancer.40 The National Cancer Control Act in Japan was established in
2006, initially focusing on major adult cancers. The second cancer
control plan in 2012 first raised the issue of care for children and
young cancer patients. Fifteen hospitals were designated as child-
hood cancer care hospitals in 2012 to increase centralization and
cooperation between all the hospitals in Japan.
In the UK, the first National Health Service cancer control plan
started in 2000. “Improving outcomes in children and young people
with cancer” was published as national guidance for cancer services
by the National Institute for Health and Clinical Excellence in 2005.
There are 20 specialized hospitals for childhood cancer, known as
principal treatment centers, and over 80 shared care centers, known
as Paediatric Oncology Shared Care Units. In Europe, similar but less
detailed standards of care for children with cancer were published in
2013,41 with an international survey of the extent of their imple-
mentation published in 2016.42 All standards recommend coordi-
nated patient care and international collaboration in research.
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In this study, we looked at the trends in cancer incidence and
survival in children over a 15-year period for Japan and England, by
using population-based cancer registry data and compared them dur-
ing the same periods for each cancer type. One limitation of our
study is the small number of records available in the Japanese data-
set. Prefectural cancer registry data were only available for 6 prefec-
tures, representing 14% of the total population,10 because other
registries did not have such long-term data with patients’ vital status
information. In 2013, a law for cancer registration was established in
Japan and a nationwide cancer registration system started in 2016.
Another limitation was the divergence between 5-year survival and
10-year survival (higher survival in 10-year survival than 5-year sur-
vival) in several cancers because we used the period approach to
predict 10-year survival in recent periods. To improve surveillance
and comparability, we need to keep collecting data widely and pre-
cisely, and follow up patients’ vital status in the long term.
In conclusion, the incidence rates of the majority of childhood
cancers differed significantly between Japan and England. Some of
these differences are explained by differences in national screening
practices (infant neuroblastoma) and known differences in the genet-
ics of Wilms tumor. Further research is needed to explore how much
these variations in incidence are due to genetic susceptibility and/or
environmental etiological factors. Regarding survival, an improvement
was observed for most cancer types during the period 1993-2008 in
both countries. The increase was particularly notable for CML, fol-
lowing the introduction of effective, targeted treatment. Variations
in survival may be due to differences in the tumor biology or in the
treatment or in the health-care service quality. The role for these
factors will be further investigated through planned collaborative
clinical and translational research between the 2 countries. Survival
remained poor for 5 main cancer types, even in recent periods. This
emphasizes the continuing need for new drug development while
other opportunities for survival improvement should not be ignored,
such as a better understanding of the potential impact of health-care
service organization and quality on survival, or through clinical stud-
ies to optimize the use of current treatments.
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